{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T07:40:20Z","timestamp":1719128420521},"reference-count":63,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2009,9,30]]},"DOI":"10.2217\/fon.09.74","type":"journal-article","created":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T16:16:59Z","timestamp":1254327419000},"page":"1039-1050","source":"Crossref","is-referenced-by-count":0,"title":["Therapy of Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adults: New Paradigms"],"prefix":"10.1080","volume":"5","author":[{"given":"Mark R","family":"Litzow","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, MN55905, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2009,9,30]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60457-2"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.381"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023001"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-130237"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.053"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403538"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22189"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20749"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.1954.1954"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12466"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20776"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.09.005"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.116"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.587.587"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.7265"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"e_1_3_2_3_17_1","first-page":"674","article-title":"Acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) after frontline therapy with hyper-CVAD regimens.","volume":"112","author":"Thomas DA","year":"2008","unstructured":"Thomas DA , O\u2019BrienS, RyttingMet al.: Acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) after frontline therapy with hyper-CVAD regimens.Blood112, 674 (2008) (Abstract 1930).","journal-title":"Blood"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70190-8"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.050"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.4.1619.bloodjournal8641619"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21932"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168625"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11960"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705769"},{"key":"e_1_3_2_3_26_1","first-page":"294","article-title":"Reduced intensity versus conventional myeloablative conditioning (RIC vs MAC) allogeneic stem cell transplantation (allo-SCT) for patients with acute lymphoblastic leukemia (ALL): a survey from the acute leukemia working party of EBMT.","volume":"112","author":"Mohty M","year":"2008","unstructured":"Mohty M , LabopinM, RuutuTet al.: Reduced intensity versus conventional myeloablative conditioning (RIC vs MAC) allogeneic stem cell transplantation (allo-SCT) for patients with acute lymphoblastic leukemia (ALL): a survey from the acute leukemia working party of EBMT.Blood112, 294 (2008) (Abstract 793).","journal-title":"Blood"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147041"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184093"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051912"},{"key":"e_1_3_2_3_30_1","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.","volume":"93","author":"Wetzler M","year":"1999","unstructured":"Wetzler M , DodgeRK, MrozekKet al.: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.Blood93, 3983\u20133993 (1999).","journal-title":"Blood"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.09.006"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05690"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.09.005"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.3441"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1102160"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.24.18_suppl.6585"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2006.12.010"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1900"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-151860"},{"key":"e_1_3_2_3_40_1","first-page":"674","article-title":"Outcome after frontline therapy with the modified hyper-CVAD regimen with or without rituximab for de novo acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL).","volume":"112","author":"Thomas DA","year":"2008","unstructured":"Thomas DA , KantarjianHM, FaderlSet al.: Outcome after frontline therapy with the modified hyper-CVAD regimen with or without rituximab for de novo acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL).Blood112, 674 (2008) (Abstract 1931).","journal-title":"Blood"},{"key":"e_1_3_2_3_41_1","first-page":"S3991","article-title":"Epratuzumab: targeting B-cell malignancies through CD22.","volume":"9","author":"Coleman M","year":"2003","unstructured":"Coleman M , GoldenbergDM, SiegelABet al.: Epratuzumab: targeting B-cell malignancies through CD22.Clin. Cancer Res.9, S3991\u2013S3994 (2003).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.05.007"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0294"},{"key":"e_1_3_2_3_44_1","first-page":"S454","article-title":"A Phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma.","volume":"25","author":"Micallef I","year":"2008","unstructured":"Micallef I , MaurerM, NikcevichD: A Phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma.J. Clin. Oncol.25, S454 (2008) (Abstract 8500).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3528"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601135447"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056754"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.56.4.249"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390904"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0006"},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2708"},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.09.001"},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.09.002"},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.56.082103.104724"},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401723"},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-8-199704150-00003"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91745-V"},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.9.2817"},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.23.2001"},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.12.1485"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.304.304"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2240"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.09.74","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:54Z","timestamp":1719125094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.09.74"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,30]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,9,30]]}},"alternative-id":["10.2217\/fon.09.74"],"URL":"https:\/\/doi.org\/10.2217\/fon.09.74","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,30]]}}}